Skip to main content
. 2019 Apr 10;12(6):828–835. doi: 10.1016/j.tranon.2019.02.007

Table 2.

Objective responsesa for all patients and for the acral and mucosal subpopulations (full-analysis set).

All Patients
N = 102 (%)
Acral
n = 38
Mucosal
n = 15
CR 1 (1.0) 0 (0) 1 (6.7)
PR 16 (15.7) 6 (15.8) 1 (6.7)
Objective response rate (CR + PR) 17 (16.7) 6 (15.8) 2 (13.3)
SD 22 (21.6) 10 (26.3) 1 (6.7)
Disease control rate (CR + PR + SD) 39 (38.2) 16 (42.1) 3 (20.0)
Progressive disease 52 (51.0) 18 (47.4) 8 (53.3)
No assessment 11 (10.8) 4 (10.5) 4 (26.7)

CR, complete response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

a

Based on RECIST v1.1 per blinded independent central review.